FOR RESEARCH USE ONLY
Constituent evidence onlySkin research

GLOW

Triple-peptide blend of BPC-157, GHK-Cu and TB500 researched for skin, hair and connective-tissue regeneration.

01Extracellular matrix02Skin models03Connective tissue
Molecular signature / glow
Structural identity

Multi-compound preparation combining repair and extracellular-matrix pathways

Also known as

BPC-157 / GHK-Cu / TB-500 · Three-compound research blend

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

GLOW is a pre-mixed triple peptide blend combining BPC-157 (10mg), GHK-Cu (50mg) and TB500 (10mg) in a single 70mg vial. The blend is studied in research contexts for its complementary effects on collagen synthesis, dermal remodelling, angiogenesis, hair-follicle support and systemic soft-tissue recovery — bringing together a cytoprotective driver (BPC-157), a copper-binding transcriptomic modulator (GHK-Cu) and a systemic cell-migration regulator (TB500) in one reconstitution.

The research question

GLOW brings together copper-mediated remodelling, cytoprotection and actin-related cell migration. Research records should identify each constituent separately so that concentration, colour and exposure are not confused by total blend mass.

Section 02

Mechanism & research themes

BPC-157 upregulates the NO system, VEGF/EGF signalling and the FAK-paxillin pathway to accelerate fibroblast migration and local tissue repair. GHK-Cu acts as a tissue-damage signal that modulates over 4,000 genes, driving collagen I/III synthesis, antioxidant SOD activity and stem-cell chemoattraction. TB500 sequesters G-actin monomers to regulate actin polymerisation, supporting angiogenesis, systemic progenitor cell recruitment and dermal remodelling.

01

Combined dermal collagen, elastin and angiogenic support

02

Synergistic hair-follicle anagen-phase extension and density signals

03

Accelerated wound closure and re-epithelialisation

04

Soft-tissue, tendon and ligament recovery from the BPC-157 / TB500 pairing

05

Transcriptome-level skin rejuvenation via GHK-Cu

06

Single-vial convenience replacing three separate reconstitutions

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Constituent evidence only

No robust controlled evidence validates the blend as a single intervention. Its rationale is assembled from separate compounds with different evidence quality and safety considerations.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 250–500mcg of the blend subcutaneously once daily, or split morning/evening, with administration adjacent to target areas (e.g. dermal or scalp regions) for localised effect. Cycles typically run 4–8 weeks on / 2–4 weeks off.

Reported persistence

BPC-157 approximately 4 hours; GHK-Cu plasma approximately 0.5–1 hour with prolonged tissue activity; TB500 approximately 30–80 minutes with multi-day depot effect.

Calculator starting point

0.3 mg per reference dose

5 doses per week · 8-week cycle

3 mL default reconstitution volume

Skin/recovery blend; 5×/week over 6–10 week cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate GLOW
Section 05

Laboratory handling

Reconstitution reference

Reconstitute the 70mg vial with 2–3mL bacteriostatic water, injected slowly down the side of the vial. Swirl gently — do not shake. Solution will take on a faint blue-green tint from the copper complex; this is expected.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Theoretical VEGF / angiogenesis caution flagged across the BPC-157 and TB500 literature — precautionary for subjects with active neoplastic tissue.

L2

GHK-Cu adds a theoretical copper-accumulation concern at chronic high systemic doses — avoid in Wilson's disease or copper-metabolism disorders.

L3

Mild injection-site redness, warmth or transient 'head rush' (TB500) may occur; tolerability is otherwise considered favourable in research.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only